Annual CFO
-$109.03 M
-$17.08 M-18.58%
December 31, 2024
Summary
- As of March 12, 2025, EWTX annual cash flow from operations is -$109.03 million, with the most recent change of -$17.08 million (-18.58%) on December 31, 2024.
- During the last 3 years, EWTX annual CFO has fallen by -$75.52 million (-225.39%).
- EWTX annual CFO is now -1088.83% below its all-time high of -$9.17 million, reached on December 31, 2019.
Performance
EWTX Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly CFO
-$26.96 M
+$417.00 K+1.52%
December 31, 2024
Summary
- As of March 12, 2025, EWTX quarterly cash flow from operations is -$26.96 million, with the most recent change of +$417.00 thousand (+1.52%) on December 31, 2024.
- Over the past year, EWTX quarterly CFO has increased by +$417.00 thousand (+1.52%).
- EWTX quarterly CFO is now -884.19% below its all-time high of -$2.74 million, reached on March 31, 2020.
Performance
EWTX Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM CFO
-$109.03 M
-$127.00 K-0.12%
December 31, 2024
Summary
- As of March 12, 2025, EWTX TTM cash flow from operations is -$109.03 million, with the most recent change of -$127.00 thousand (-0.12%) on December 31, 2024.
- Over the past year, EWTX TTM CFO has dropped by -$127.00 thousand (-0.12%).
- EWTX TTM CFO is now -3880.58% below its all-time high of -$2.74 million, reached on March 31, 2020.
Performance
EWTX TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Cash From Operations Formula
CFO = Net Income + Non Cash Expenses + Changes In Working Capital
EWTX Cash From Operations Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -18.6% | +1.5% | -0.1% |
3 y3 years | -225.4% | -22.2% | -41.6% |
5 y5 years | -1088.8% | -22.2% | -41.6% |
EWTX Cash From Operations Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -225.4% | at low | -186.2% | +5.7% | -225.4% | at low |
5 y | 5-year | -1088.8% | at low | -884.2% | +5.7% | -3880.6% | at low |
alltime | all time | -1088.8% | at low | -884.2% | +5.7% | -3880.6% | at low |
Edgewise Therapeutics Cash From Operations History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Dec 2024 | -$109.03 M(+18.6%) | -$26.96 M(-1.5%) | -$109.03 M(+0.1%) |
Sep 2024 | - | -$27.37 M(+4.9%) | -$108.90 M(+5.1%) |
Jun 2024 | - | -$26.10 M(-8.7%) | -$103.58 M(+6.0%) |
Mar 2024 | - | -$28.60 M(+6.6%) | -$97.72 M(+6.3%) |
Dec 2023 | -$91.95 M(+74.7%) | -$26.83 M(+21.6%) | -$91.95 M(+19.5%) |
Sep 2023 | - | -$22.06 M(+9.0%) | -$76.97 M(+15.1%) |
Jun 2023 | - | -$20.23 M(-11.4%) | -$66.88 M(+6.3%) |
Mar 2023 | - | -$22.83 M(+92.5%) | -$62.89 M(+19.5%) |
Dec 2022 | -$52.63 M | -$11.86 M(-0.9%) | -$52.63 M(+4.9%) |
Sep 2022 | - | -$11.96 M(-26.4%) | -$50.20 M(+8.0%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2022 | - | -$16.25 M(+29.2%) | -$46.50 M(+16.2%) |
Mar 2022 | - | -$12.57 M(+33.5%) | -$40.02 M(+19.4%) |
Dec 2021 | -$33.51 M(+129.0%) | -$9.42 M(+14.0%) | -$33.51 M(+16.6%) |
Sep 2021 | - | -$8.26 M(-15.4%) | -$28.73 M(+21.0%) |
Jun 2021 | - | -$9.77 M(+61.3%) | -$23.74 M(+32.2%) |
Mar 2021 | - | -$6.06 M(+30.6%) | -$17.95 M(+22.7%) |
Dec 2020 | -$14.63 M(+59.6%) | -$4.64 M(+41.7%) | -$14.63 M(+46.4%) |
Sep 2020 | - | -$3.27 M(-17.9%) | -$10.00 M(+48.7%) |
Jun 2020 | - | -$3.98 M(+45.5%) | -$6.72 M(+145.5%) |
Mar 2020 | - | -$2.74 M | -$2.74 M |
Dec 2019 | -$9.17 M | - | - |
FAQ
- What is Edgewise Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Edgewise Therapeutics?
- What is Edgewise Therapeutics annual CFO year-on-year change?
- What is Edgewise Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Edgewise Therapeutics?
- What is Edgewise Therapeutics quarterly CFO year-on-year change?
- What is Edgewise Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Edgewise Therapeutics?
- What is Edgewise Therapeutics TTM CFO year-on-year change?
What is Edgewise Therapeutics annual cash flow from operations?
The current annual CFO of EWTX is -$109.03 M
What is the all time high annual CFO for Edgewise Therapeutics?
Edgewise Therapeutics all-time high annual cash flow from operations is -$9.17 M
What is Edgewise Therapeutics annual CFO year-on-year change?
Over the past year, EWTX annual cash flow from operations has changed by -$17.08 M (-18.58%)
What is Edgewise Therapeutics quarterly cash flow from operations?
The current quarterly CFO of EWTX is -$26.96 M
What is the all time high quarterly CFO for Edgewise Therapeutics?
Edgewise Therapeutics all-time high quarterly cash flow from operations is -$2.74 M
What is Edgewise Therapeutics quarterly CFO year-on-year change?
Over the past year, EWTX quarterly cash flow from operations has changed by +$417.00 K (+1.52%)
What is Edgewise Therapeutics TTM cash flow from operations?
The current TTM CFO of EWTX is -$109.03 M
What is the all time high TTM CFO for Edgewise Therapeutics?
Edgewise Therapeutics all-time high TTM cash flow from operations is -$2.74 M
What is Edgewise Therapeutics TTM CFO year-on-year change?
Over the past year, EWTX TTM cash flow from operations has changed by -$127.00 K (-0.12%)